Drugs / Pluripotent Stem Cell-derived Mesenchymal Stem Cell Exosome
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05738629 | Mar 2023 → Feb 2025 | dry eye syndrome | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pluripotent Stem Cell-derived Mesenchymal Stem Cell Exosome | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05738629 ↗ |
| Known as | PSC-MSC-Exo | “Pluripotent Stem Cell-derived Mesenchymal Stem Cell Exosome (PSC-MSC-Exo) Eye Drops” NCT05738629 ↗ |
| Modality | Other / unclassified | “Pluripotent Stem Cell-derived Mesenchymal Stem Cell Exosome (PSC-MSC-Exo) Eye Drops” NCT05738629 ↗ |
| Route | Other | “PSC-MSC-Exo eye drops 0.125 ml/single eye/one time” NCT05738629 ↗ |